Re: Daily ibuprofen may prevent Alzheimer disease

Dr McGeer and colleagues report on a study of the neuroinflammatory process leading to the cognitive deficits that define Alzheimer disease clinical onset in an article titled “Alzheimer’s disease can be spared by nonsteroidal anti-inflammatory drugs,” published in the Journal of Alzheimer Disease.

They recommend that people get tested for peptide amyloid beta protein 42 (Abeta 42) in saliva at age 55, 10 years prior to the usual age of 65 when the onset of Alzheimer disease would typically occur. If it’s elevated, these people should take daily ibuprofen to ward off the disease, according to a related News item published in the BCMJ [2018;60:191].

In March 2017 the European Society of Cardiology issued a press release titled “‘Harmless’ painkillers associated with increased risk of cardiac arrest, with specific reference to ibuprofen and diclofenac.”

On 5 November 2017, the FDA strengthened labels warning that (nonaspirin) NSAIDs, used for the temporary relief of pain and fever, can increase the risk of heart attack, stroke, and death.

In addition, elderly people may have increased cardiovascular risk and disease.

In their article, Dr McGeer’s team states “we are currently investigating whether NSAID consumption can affect these levels [of Abeta 42].”

Hence, the general public should be cautioned not to jump into action by taking daily ibuprofen to prevent Alzheimer disease until Dr McGeer’s investigation has been completed. It is not clear if long-term daily use of ibuprofen associates with significant cardiovascular side effects.
—H.C. George Wong, MD, FRCPC

Dr McGeer has read Dr Wong’s letter and agrees with his comments. —ED.

H.C. George Wong, MD, FRCPC. Re: Daily ibuprofen may prevent Alzheimer disease. BCMJ, Vol. 60, No. 6, July, August, 2018, Page(s) 289 - Letters.

Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.

For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit

BCMJ Guidelines for Authors

Leave a Reply